Skip to Content
  • Title
    EVP, Worldwide Chairman, Pharmaceuticals
  • Affiliation
    Johnson & Johnson
  • Age

Taubert has seen some ups and downs since taking over J&J’s pharma business in 2018. At $40.7 billion, it accounts for about half of the company’s revenue. Her segment has come under scrutiny for its culpability in the opioid crisis; J&J was ordered to pay a $572 million judgment last month in Oklahoma (those charges predate Taubert’s tenure in the role). The upside: Two new J&J drugs have been approved so far in 2019.

Subscribe to The Broadsheet, our newsletter on the world’s most powerful women.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access